Improving oncology outcomes through targeted therapeutics will require electronic delivery systems

Future Oncology

Volumn 7, Issue 5, 2011, Pages 649-656

  Rooij, Tibor Van ^a   Marsh, Sharon ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

clinical decision support; eHealth; electronic health records; medical informatics; oncology; personalized medicine; pharmacogenomics; targeted therapeutics; translation

Indexed keywords

ARSENIC TRIOXIDE; BUSULFAN; CAPECITABINE; CETUXIMAB; DASATINIB; ERLOTINIB; GEFITINIB; IMATINIB; IRINOTECAN; LAPATINIB; MERCAPTOPURINE; NILOTINIB; PANITUMUMAB; TAMOXIFEN; TRASTUZUMAB;

DRUG DELIVERY SYSTEM; ELECTRONIC MEDICAL RECORD; FOOD AND DRUG ADMINISTRATION; GENOTYPE; HUMAN; INFORMATION TECHNOLOGY; MOLECULARLY TARGETED THERAPY; OUTCOME ASSESSMENT; PHARMACOGENOMICS; PHYSICIAN; POINT OF CARE TESTING; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SOCIOECONOMICS; WORKFLOW;

DRUG DELIVERY SYSTEMS; ELECTRONIC HEALTH RECORDS; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; NEOPLASMS; TREATMENT OUTCOME;

EID: 79956072020     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.37     Document Type: Review

References (51)

1. Gowing, JD: What are we waiting for? Rep. Card. Cancer Canada 12, 4 (2009-2010).
2. Evans WE, McLeod HL: Pharmacogenomics - drug disposition, drug targets, and side effects. N. Engl. J. Med. 28, 1-12 (2003).
3. Marsh S, van Rooij T: Challenges of incorporating pharmacogenomics into clinical practice. Gastrointest. Cancer Res. 3, 206-207 (2009).
4. Marsh S: Impact of pharmacogenomics on clinical practice in oncology. Mol. Diag. Ther. 11, 79-82 (2007). (Pubitemid 46572568)
5. Al Mallah A, Guelpa P, Marsh S, van Rooij T: Integrating genomic-based clinical decision support into electronic health records. Personalized Med. 7, 163-170 (2010).
6. Katsios C, Zoras O, Roukus DH: Cancer genome sequencing and potential application in oncology. Future Oncol. 6, 1527-1531 (2010).
7. Augusto JC, Black ND, McAllister HG, McCullagh PJ, Nugent CD: Pervasive health management: new challenges for health informatics. J. Univers. Comput. Sci. 12, 1-5 (2006). (Pubitemid 43296762)
8. Van Rooij T: Behind the PGx challenge: Biofx. Genome Technol. 19-20 (2007).
9. Wilke RA, Xu H, Denny JC, et al.: The emerging role of electronic medical records in pharmacogenomics. Clin. Pharmacol. Ther. 89(3), 379-386 (2011).
10. Wright A, Sittig DF: SANDS: A service-oriented architecture for clinical decision support in a National Health Information Network. J. Biomed. Inform. 41, 962-981 (2008).
11. Payne TH, Detmer DE, Wyatt JC, Buchan IE: National-scale clinical information exchange in the United Kingdom: lessons for the United States. J. Am. Med. Inform. Assoc. 18, 91-98 (2011).
12. Mansour JC, Schwarz RE: Molecular mechanisms for individualized cancer care. J. Am. Coll. Surg. 207, 250-258 (2008).
13. Vant Veer LJ, Bernards R: Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 452, 564-570 (2008). (Pubitemid 351483370)
14. Marsh S, Hoskins JM: Irinotecan pharmacogenomics. Pharmacogenomics 11, 1003-1010 (2010).
15. Pirmohamed M: The applications of Pharmacogenetics to prescribing: what is currently practicable? Clin. Med. 9, 493-495 (2009).
16. Toffoli G, Cecchin E, Gasparini G, et al.: Genotype-driven Phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. J. Clin. Oncol. 28, 866-871 (2010).
17. Hazama S, Nagashima A, Kondo H, et al.: Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1*28 polymorphism. Cancer Sci. 101, 722-727 (2010).
18. Langley MR, Booker JK, Evans JP, McLeod HL, Weck KE: Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms. J. Mol. Diagn. 11, 216-225 (2009).
19. Marsh S, Liu G: Pharmacokinetics and pharmacogenomics in breast cancer chemotherapy. Adv. Drug Deliv. Rev. 61, 381-387 (2009).
20. Müller MC, Cross NC, Erben P, et al.: Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 23, 1957-1963 (2009).
21. Amir-Aslani A, Mangematin V: The future of drug discovery and development: shifting emphasis towards personalized medicine. Technol. Forecast. Soc. Change. 77, 203-217 (2010).
22. Osheroff JA, Teich JM, Middleton B, Steen EB, Wright A, Detmer DE: A roadmap for national action on clinical decision support. J. Am. Med. Inform. Assoc. 14, 141-145 (2007). (Pubitemid 46275496)
23. Garg AX, Adhikari NKJ, McDonald H, et al.: Effects of computerized clinical decision support systems on practitioner performance and patient outcomes: a systematic review. JAMA 293, 1223-1238 (2005). (Pubitemid 40327908)
24. Emery J, Walton R, Murphy M, et al.: Computer support for interpreting family histories of breast and ovarian cancer in primary care: comparative study with simulated cases. BMJ 321, 28-32 (2000). (Pubitemid 30417024)
25. Kawamoto K, Lobach D, Willard H, Ginsburg G: A national clinical decision support infrastructure to enable the widespread and consistent practice of genomic and personalized medicine. BMC Med. Inform. Decis. Mak. 9, 17 (2009).
26. Wright A, Sittig DF, Ash JS, Sharma S, Pang JE, Middleton B: Clinical decision support capabilities of commercially-available clinical information systems. J. Am. Med. Inform. Assoc. 16, 637-644 (2009).
27. Voos J, Riva G, Zerbini C, Centeno C, Gonzalez E: Custom HL7 V3 message provider using web services security features. Conf. Proc. IEEE Eng. Med. Biol. Soc. 1, 3899-3902 (2010).
28. Walderhaug S, Hartvigsen G, Stav E: Model-driven traceability in healthcare information systems development. Stud. Health. Technol. Inform. 160, 242-246 (2010).
29. Jenders RA, Del Fiol G, Kawamoto K, Sailors RM: Standards in clinical decision support: activities in health level seven. AMIA Annu. Symp. Proc. 1244-1245 (2008).
30. Jha AK, DesRoches CM, Campbell EG, et al.: Use of electronic health records in U.S. hospitals. N. Engl. J. Med. 360, 1628-1638 (2009).
31. Kawamoto K, Honey A, Rubin K: The HL7-OMG Healthcare Services Specification Project: motivation, methodology, and deliverables for enabling a semantically interoperable service-oriented architecture for healthcare. J. Am. Med. Inform. Assoc. 16, 874-881 (2009).
32. Robertson J, Moxey AJ, Newby DA, Gillies MB, Williamson M, Pearson SA: Electronic information and clinical decision support for prescribing: state of play in Australian general practice. Fam. Pract. 28, 93-101 (2011).
33. Rajeev D, Staes CJ, Evans RS, et al.: Development of an electronic public health case report using HL7 v2.5 to meet public health needs. J. Am. Med. Inform. Assoc. 17, 34-41 (2010).
34. Lesko LJ: Personalized medicine: elusive dream or imminent reality? Clin. Pharmacol. Ther. 81, 807-816 (2007). (Pubitemid 46788303)
35. Titler MG: Translation science and context. Res. Theory Nurs. Pract. 24, 35-55 (2010).
36. Epstein RS, Teagarden JR: Comparative effectiveness research and personalized medicine: catalyzing or colliding? Pharmacoeconomics 28, 905-913 (2010).
37. de la Calle G, van Mulligen EM, Molero E, et al.: Education and research in InfoBiomed, the European Network of Excellence in Biomedical Informatics. AMIA Annu. Symp. Proc. 11, 927 (2007).
38. Maojo V, Crespo J, de la Calle G, Barreiro J, Garcia-Remesal M: Using web services for linking genomic data to medical information systems. Methods Inf. Med. 46, 484-492 (2007). (Pubitemid 47300368)
39. Gurwitz D, Bregman-Eschet Y: Personal genomics services: whose genomes? Eur. J. Hum. Genet. 17, 883-889 (2009).
40. Patch C, Sequeiros J, Cornel MC: Genetic horoscopes: is it all in the genes? Points for regulatory control of direct-to-consumer genetic testing. Eur. J. Hum. Genet. 17, 857-859 (2009).
41. Farkas DH, Holland CA: Direct-to-consumer genetic testing: two sides of the coin. J. Mol. Diagn. 11, 263-265 (2009).
42. Ng PC, Murray SS, Levy S, Venter JC: An agenda for personalized medicine. Nature 461, 724-726 (2009).
43. Zhang W, Dolan ME: Impact of the 1000 genomes project on the next wave of pharmacogenomic discovery. Pharmacogenomics 11, 249-256 (2010).
44. Frueh FW: Back to the future: why randomized controlled trials cannot be the answer to pharmacogenomics and personalized medicine. Pharmacogenomics 10, 1077-1081 (2009).
45. FDA-approved biomarkers www.fda.gov/Drugs/ScienceResearch/ ResearchAreas/Pharmacogenetics/ ucm083378.htm
46. Presidents Council of Advisors on Science and Technology: Priorities for Personalized Medicine (2008) www.whitehouse.gov/files/documents/ostp/ PCAST/pcast-report-v2.pdf
47. Presidents Council of Advisors on Science and Technology: Report to the president realizing the full potential of health information technology to improve healthcare for Americans: the path forward (2010) www.whitehouse.gov/ sites/default/files/ microsites/ostp/pcast-health-it-report.pdf
48. LabCorp homepage www.labcorp.com/wps/portal
49. Prometheus homepage www.prometheuspatients.com/Products- Diagnostics.asp
50. Third Wave Technologies homepage www.twt.com
51. Medco homepage www.medcohealth.com/medco/corporate/home.jsp